Traders Sell Pfizer (PFE) on Strength (PFE)
Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading on Thursday. $66.34 million flowed into the stock on the tick-up and $170.47 million flowed out of the stock on the tick-down, for a money net flow of $104.13 million out of the stock. Of all equities tracked, Pfizer had the 6th highest net out-flow for the day. Pfizer traded up $0.44 for the day and closed at $42.85
A number of equities analysts recently issued reports on PFE shares. JPMorgan Chase & Co. reissued a “$37.66” rating on shares of Pfizer in a report on Wednesday, July 18th. Morgan Stanley reissued a “buy” rating and issued a $43.00 price objective on shares of Pfizer in a report on Monday, June 11th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a report on Tuesday, July 3rd. Cantor Fitzgerald set a $45.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, June 13th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $42.00 price objective on shares of Pfizer in a report on Thursday, July 19th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the stock. Pfizer has a consensus rating of “Hold” and a consensus target price of $41.89.
The company has a market capitalization of $251.87 billion, a P/E ratio of 16.17, a P/E/G ratio of 2.03 and a beta of 0.96. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.41.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 4th. Shareholders of record on Friday, August 3rd were paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.17%. The ex-dividend date of this dividend was Thursday, August 2nd. Pfizer’s payout ratio is 51.32%.
In other news, VP Loretta V. Cangialosi sold 26,814 shares of Pfizer stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $40.16, for a total transaction of $1,076,850.24. Following the sale, the vice president now owns 102,360 shares in the company, valued at $4,110,777.60. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Laurie J. Olson sold 10,214 shares of Pfizer stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the sale, the insider now owns 72,672 shares in the company, valued at approximately $2,979,552. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 761,230 shares of company stock worth $29,054,690. 0.06% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the company. Ballew Advisors Inc bought a new stake in shares of Pfizer during the first quarter valued at approximately $102,000. Earnest Partners LLC bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $105,000. Woodard & Co. Asset Management Group Inc. ADV bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $118,000. Fort L.P. bought a new stake in shares of Pfizer during the second quarter valued at approximately $121,000. Finally, Delpha Capital Management LLC bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $126,000. Hedge funds and other institutional investors own 69.14% of the company’s stock.
Pfizer Company Profile (NYSE:PFE)
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Further Reading: What are the most popular ETFs
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.